<DOC>
	<DOC>NCT02404935</DOC>
	<brief_summary>National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed by progression-free survival at 6 months after start of maintenance therapy.</brief_summary>
	<brief_title>Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1. Histologically confirmed colorectal cancer 2. KRAS and NRAS wildtype genes after analysis of mutation status from the primary tumour or metastasis 3. Non resectable metastatic disease in a curative intent 4. No prior chemotherapy except for fluoropyrimidines with or without oxaliplatinbased adjuvant treatment earlier than 6 months ago from inclusion date 5. Patient presenting with at least one measurable tumour target (greater than 20 mm) according to RECIST criteria, which has never been irradiated 6. Patient with a greater than 3 month life expectancy 7. Performance Status less or equal to 2 8. Male or female 18 years or older 9. Acceptable blood test 10. Patient who has signed a written informed consent form 1. Known and/or symptomatic brain metastases 2. Known allergy to one of treatment components 3. Neurological or psychiatric condition which could interfere with good treatment compliance 4. Patient currently in treatment with any other antitumour therapy: chemotherapy or targeted therapy or radiotherapy ≤ 14 days before randomisation 5. Other serious conditions such as: respiratory failure. History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan. 6. Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrolment/randomisation 7. Concomitant severe infection. 8. History of cancer (except skin cancer other than melanoma or an in situ cervical epithelioma or other solid tumour treated for curative purposes without signs of the condition and with no treatment administered in the 5 years before randomisation.) 9. Patient already included in another clinical trial with an investigational molecule 10. Prior treatment with antiEGFr antibodies (e.g. panitumumab (Vectibix® or cetuximab / Erbitux® ) or treatment with small EGFr inhibitor molecules (e.g., erlotinib / Tarceva®) 11. Pregnant female, likely to be or currently breast feeding, or planning to become pregnant within 6 months after the end of treatment or absence of effective contraception for males and females of childbearing age during treatment and for 6 months (male or female) after the end of treatment 12. Those deprived of their freedom or under guardianship 13. Impossibility of undergoing trial's medical followup for geographical, social or psychological reasons</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>cetuximab</keyword>
	<keyword>maintenance</keyword>
</DOC>